Quarterly report pursuant to Section 13 or 15(d)

Supplemental Disclosure for Statements of Cash Flows (Details)

Supplemental Disclosure for Statements of Cash Flows (Details) (USD $)	3 Months Ended		1 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015
Class of Stock [Line Items]
Cash paid during the period for interest	$ 701,000us-gaap_InterestPaid	$ 907,000us-gaap_InterestPaid
Issued stock to 401(k) plan, shares	68,157
Issued stock to 401(k) plan value	117,099
Derivative liabilities	63,000us-gaap_DerivativeLiabilities		63,000us-gaap_DerivativeLiabilities
Deemed dividend on beneficial conversion feature of MT Preferred Stock	(46,000)	0
Convertible Preferred Stock
Class of Stock [Line Items]
Deemed dividend on beneficial conversion feature of MT Preferred Stock			46,000
Macrophage Therapeutics \| Convertible Preferred Stock
Class of Stock [Line Items]
Deemed dividend on beneficial conversion feature of MT Preferred Stock			$ 46,000

- Definition

Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.

+ References + Details